Price Alert

Tourmaline Bio Inc. (TRML)

NASDAQ: TRML · Real-Time Price · USD

47.78

-0.05 (-0.10%)

At close: Oct 01, 2025, 1:45 PM

-0.10% (1D)

Bid	47.77
Market Cap	1.23B
Revenue (ttm)	40K
Net Income (ttm)	-88.47M
EPS (ttm)	-3.45
PE Ratio (ttm)	-13.85
Forward PE	-11.41
Analyst	Hold
Dividends	n/a

Ask	47.79
Volume	294,578
Avg. Volume (20D)	987,460.2
Open	47.80
Previous Close	47.83
Day's Range	47.76 - 47.87
52-Week Range	11.56 - 48.27
Beta	2.06
Ex-Dividend Date	n/a

About TRML

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TRML

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TRML stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+57.85%

Tourmaline shares are trading higher after the com... Unlock content with Pro Subscription

4 months ago

-2.59%

TRML stock has given up its prior loss. Tourmaline Bio shares were trading lower. The company announced topline results from its ongoing Phase 2 TRANQUILITY trial.

News

2 weeks ago · businesswire.com

TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...

2 weeks ago · zacks.com

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

3 weeks ago · investopedia.com

This Small Biotech Stock Is Surging Today. Here's Why.

Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is...

3 weeks ago · seekingalpha.com

Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal

Nebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentially expanding to $19.4B. Novartis acquires Tourmaline Bio for $1.4B in cash, a 59% premium, highligh...

3 weeks ago · proactiveinvestors.co.uk

Novartis strikes $1.4bn deal for Tourmaline Bio

Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthening its push into cardiovascular medicine with a late-stage anti-inflammatory drug candidate. The S...

3 weeks ago · businesswire.com

Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Tourmaline (NASDAQ: TRML) for possible breaches of fiduciary duty and other violations of law in its transaction with a Novartis. Click here...

3 weeks ago · reuters.com

Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion

Switzerland's Novartis will acquire Tourmaline Bio with an offer price of $48 per share, in a deal valuing the New York-based company at $1.4 billion on a fully diluted basis, it said on Tuesday.

1 month ago · zacks.com

Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...